Skip to main content

Table 6 Univariate and multivariate analysis of baseline factors associated with anatomic success and best corrected visual acuity improvement ≥15 letters. Factors associated with success in the univariate analysis at p ≤ 0.1 were included in the multivariate analysis

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Factor Anatomic success BCVA gaining ≥ 15 letters
Univariate Univariate
OR (95% CI) P OR (95% CI) P
Sex
Ref: Women     
  Men 0.48 (0.15 to 1.52) 0.2103 2.55 (0.83 to 7.79) 0.1013
Agea
  > 73 years 2.2 (0.69 to 7.25) 0.1779 0.57 (0.19 to 1.71 0.3132
ME durationa
  > 32 days 0.40 (0.12 to 1.31) 0.1300 1.44 (0.48 to 4.29) 0.5148
ME Duration
Ref: ≤ 30 days     
   > 30 ≤ 60 0.27 (0.05 to 1.39) 0.1177 2.64 (0.57 to 12.25) 0.2555
   > 60 0.33 (0.09 to 1.22) 0.0955 0.91 (0.26 to 3.139 0.8745
ME duration
Ref: ≤ 90 days     
   > 90 days 0.39 (0.11 to 1.41) 0.1501 0.48 (0.12 to 1.98) 0.3082
RVO
Ref: CRVO     
  BRVO 1.88 (0.54 to 6.50) 0.3193 1.69 (0.46 to 6.23) 0.4287
ME Subtype
Ref: SLRS     
  CME 2.33 (0.12 to 43.79) 0.5711 1.00 (0.98 to 1.02) 0.9981
  SRD 2.50 (0.14 to 43.97) 0.5311 1.00 (0.98 to 1.02) 0.9981
Treatment status
Ref: Naïve     
  Previously treated 1.29 (0.41 to 4.07) 0.6613 0.36 (0.12 to 1.16) 0.0864
ELM status
Ref: Non-disrupted     
  Partially disrupted 0.73 (0.15 to 3.47) 0.6911 5.69 (0.62 to 52.34) 0.1248
  Disrupted 0.56 (0.11 to 2.72) 0.4692 19.5 (2.11 to 179.91) 0.0088
Baseline BCVAa
  > 60 0.66 (0.21 to 2.06) 0.4702 0.03 (0.00 to 0.21) 0.0007
DRIL
Ref: No     
  Yes 1.36 (0.39 to 4.74) 0.7280 2.84 (0.86 to 9.44) 0.0880
DRIL Location
Ref: only INL/ONL     
  Both affected 1.05 (0.33 to 3.33) 0.9340 0.36 (0.07 to 1.82) 0.2186
HRF
Ref: < 10     
  10–20 4.75 (1.11 to 20.39) 0.0361 0.96 (0.24 to 3.83) 0.9567
   > 20 2.60 (0.63 to 10.79) 0.1881 1.76 (0.43 to 7.19) 0.4313
HRF Location
Ref: only INL/ONL     
  Both affected 1.01 (0.31 to 3.32) 0.9830 0.72 (0.23 to 2.23) 0.5684
SRF
Per μm thicker 1.00 (0.99 to 1.01) 0.4303 0.99 (0.99 to 1.01) 0.6753
SRF
  > 119 μm 2.97 (0.62 to 14.22) 0.1732 3.11(0.72 to 13.44) 0.1285
Cysts
Ref: < 100     
  100–200 1.00 (0.05 to 19.96) 1.000 1.00 (0.98 to 1.02) 0.9981
   > 200 3.67 (0.21 to 64.55) 0.3746 0.99 (0.99 to 1.01) 0.9979
Change in Septum M6
Ref: No     
  Yes 13.93 (2.78 to 69.83) 0.0014 1.97 (0.65 to 5.959 0.2300
  1. Multivariate analysis:
  2. • Anatomic success:
  3. MD Duration > 60 days: OR: 0.34; 95% CI: 0.08 to 1.35; p = 0.1234
  4. HRF 10–20: OR: 4.26; 95% CI: 0.88 to 25.60; p = 0.0712
  5. Change in Septum month 6: OR: 1.09; 95% CI: 0.31 to 3.83; p = 0.8939
  6. • BCVA gaining ≥15 letters:
  7. Baseline BCVA: OR: 0.04; 95% CI: 0.00 to 0.39; p = 0.0057
  8. Treatment status: OR: 0.46; 95% CI: 0.19 to 1.96; p = 0.3003
  9. ELM status (Disrupted): 5.78; 95% CI: 0.48 to 69.77; p = 0.1670
  10. DRIL: OR: 1.29; 95% CI: 0.26 to 6.54; p = 0.7571
  11. Age: OR: 2.96; 95% CI: 0.92 to 9.57; p = 0.0695
  12. Duration of ME: OR: 2.65; 95% CI: 0.82 to 8.58; p = 0.1036
  13. Abbreviations: OR Odds ratio, CI Confidence interval, ME Macular edema, SLRS Sponge-like retinal swelling, CME Cystoid macular edema, SRD Serous retinal detachment, DRIL. Disorganization of inner retinal layer, INL Inner nuclear layer, ONL Outer nuclear layer, HRF Hyperreflective foci, SRF Subretinal fluid, M Month
  14. aReference group ≤ Median